Aarti Drugs has announced that its Board of Directors will hold a meeting on February 3, 2026, to consider and approve the audited financial results (standalone and consolidated) for Q3 FY26 (October-December 2025) and the nine months ended December 31, 2025. The board will also consider declaring an interim dividend for the financial year 2025-26, if any.
Board Meeting Scheduled
Aarti Drugs has scheduled a meeting of its Board of Directors to be held on Tuesday, February 3, 2026. The key agenda of the meeting includes reviewing and approving the company’s financial performance and considering a potential dividend payout.
Financial Results on the Agenda
The Board will review and approve the audited financial results, both standalone and consolidated, for the quarter ended December 31, 2025 (Q3 FY26), and for the nine-month period ending on the same date. This will provide stakeholders with an update on the company’s financial health and operational performance.
Interim Dividend Consideration
In addition to the financial results, the Board will also consider the declaration of an interim dividend for the financial year 2025-26. The decision regarding the dividend will be based on the company’s performance and financial position.
Trading Window Closure
As per the company’s prior intimation on December 29, 2025, the trading window remains closed and will re-open 48 hours after the declaration of the financial results. This is to ensure fair trading practices and prevent insider trading.
Source: BSE
